Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LactiSal vs Clotrimazole for Vulvovaginal Candidiasis
NCT02907307Phase 3Withdrawn
- Sponsor
- Medinova AG
- Start
- Dec 2018
- Primary completion
- Dec 2019
01
Overview
Phase 3, randomised, open-label trial in vulvovaginal candidiasis (VVC) (3 arms), sponsored by Medinova AG. Primary endpoint: Clinical cure rate at 10 days. Planned start Dec 2018; status: withdrawn.
02
Conditions
vulvovaginal candidiasis (VVC)
Beyond the preview
Go deeper on NCT02907307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02907307.